COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 2 of 14 for:    mark stegall transplant

Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00670774
Recruitment Status : Completed
First Posted : May 2, 2008
Results First Posted : June 26, 2018
Last Update Posted : June 26, 2018
Alexion Pharmaceuticals
Information provided by (Responsible Party):
Mark Stegall, Mayo Clinic

Brief Summary:

A strongly positive crossmatch has long been considered an absolute contraindication to kidney transplantation and most patients with anti-human leukocyte antigen (HLA) antibody never were able to receive a kidney transplant. Over the past decade, significant progress has been made in overcoming early antibody-mediated renal allograft injury. Our group has performed more than 200 such transplants providing the possibility of transplant to previously untransplantable patients. Despite our best efforts, transplantation in these patients is still complicated by a high rate of acute humoral rejection (AHR).

Patients included in this study will be those who have demonstrable anti-HLA antibody specific for their living donor. It is our hypothesis that blockade of terminal complement activation at the time of transplant in combination with our current protocols will reduce the incidence of AHR in patients with anti-donor HLA antibody.

Condition or disease Intervention/treatment Phase
Kidney Transplant Drug: Eculizumab Phase 1 Phase 2

Detailed Description:

The eculizumab dosing regimen was modified from that used in the treatment of paroxysmal nocturnal hemoglobinuria and consisted of 1200 mg immediately prior to transplantation, 600 mg on postoperative day 1, and 600 mg weekly thereafter for 4 weeks. At week 4, assessment of DSA levels was performed. Eculizumab was discontinued in patients whose DSA had significantly decreased (B flow crossmatch channel shift<200). In patients with persistently high DSA and thus believed to have continued high risk for AMR, eculizumab treatment continued (1200 mg week 5, and then every 2 weeks). Another DSA assessment was performed at week 9 and eculizumab was discontinued if the B flow crossmatch channel shift was <200.

The eculizumab group were compared to a historical control group consisting of consecutive transplants between 1/1/2005 and 1/10/2017 who met the inclusion criteria. The historical control group had been treated with a similar plasma exchange based protocol without eculizumab.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection (AMR) in Positive Crossmatch Living Donor Kidney Transplantation
Actual Study Start Date : March 2008
Actual Primary Completion Date : May 2017
Actual Study Completion Date : August 2017

Arm Intervention/treatment
Experimental: Eculizumab
Patients received eculizumab intravenously according to details provided in the intervention description.
Drug: Eculizumab
  • Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.
  • Patients will be given 900 mg of eculizumab on Day 1 post-transplant.
  • Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant
  • At week 4, patients will be assessed for B cell flow cytometry cross match (FCXM). Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FCXM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar "discontinuation assessments" will be performed at week 9, 26, 39 and 52.
  • In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period
Other Name: Soliris

Primary Outcome Measures :
  1. Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation [ Time Frame: up to 3 months ]
    AMR can cause acute graft loss or shorten allograft survival. Renal allograft biopsies were obtained percutaneously using ultrasound guidance processed for light microscopy and immunofluorescence for peritubular capillary staining for C4d. All biopsies were reviewed by a pathologist in a blinded fashion. AMR was diagnosed using standard Banff criteria in combination with graft dysfunction (increase in serum creatinine >/=0.3 mg/dL over nadir.)

Secondary Outcome Measures :
  1. Number of Patients Developing High DSA Levels at Less Than or Equal to 3 Months [ Time Frame: 3 months ]
    High DSA levels were defined as B flow cross match channel shift >350 at any time point in the first 3 months.

  2. Number of Patients Requiring Splenectomy [ Time Frame: 1 year ]
    A splenectomy is a surgical operation involving removal of the spleen. Splenectomy was performed for severe AMR in the setting of a rising serum creatinine (usually >2.0) and a rising serum DSA level despite daily plasma exchange treatments.

  3. Graft Dysfunction in First Month Post Transplant [ Time Frame: 1 month ]
    (Maximum serum creatinine-nadir serum creatinine)

  4. Length of Follow-up [ Time Frame: up to 15 months ]
    Following the completion of dosing, subjects were to return for follow-up visits at 3 and 6 months post transplant to obtain biopsies and collect follow-up data. Subjects who continued the drug for 12 months were to receive their final assessment at 15 months.

  5. Number of Subjects With Graft Survival at One Year [ Time Frame: 1 year ]
    Graft survival means the kidney has not been rejected by the body.

  6. Number of Subjects Receiving Posttransplant Plasma Exchange (PE) [ Time Frame: up to one year ]
    Plasma exchange is needed when there is poor kidney functioning, and donor specific alloantibody (DSA) is high

  7. Transplant Glomerulopathy Incidence at One Year [ Time Frame: 1 year ]
    Transplant glomerulopathy is a morphologic lesion of renal allografts that is characterized histologically by duplication and/or multilayering of the glomerular basement membrane. It is widely accepted as a manifestation of chronic antibody-mediated rejection (AMR). This is determined by histology.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. 18 years of age
  2. Has end stage renal disease (ESRD) and is to receive a kidney transplant from a living donor (LD) to whom he/she has either:

    1. A positive crossmatch requiring pretransplant desensitization (defined as a positive T-cell FCXM of greater than or equal to 300 but less than 450 prior to desensitization, or as a positive B-cell FCXM of > 300 but < 450 prior to desensitization with demonstrable Class II donor specific alloantibody (DSA) on solid-phase assays). Subsequent to desensitization, patient must have, at the time of transplant, a T-cell and B-cell FCXM less than 300; or
    2. A positive crossmatch not requiring desensitization (defined as FCXM between 200 and 299)
  3. Willing to comply with the protocol
  4. Females of child-bearing potential must have a negative pregnancy test (serum β-HCG) and sexually active females must agree to use a reliable and medically approved method of contraception
  5. Willing and able to give written informed consent
  6. Vaccinated against Neisseria meningitides (quadrivalent vaccine), Pneumococcus or H. influenzae at least two weeks prior to beginning desensitization

Exclusion Criteria:

  1. Unstable cardiovascular condition
  2. Previous splenectomy
  3. Active bacterial or other infection which is clinically significant in the opinion of the investigator
  4. Known or suspected hereditary complement deficiency
  5. Participation in any other investigational drug study or was exposed to an investigational drug or device within 30 days of randomization
  6. Pregnant, breast-feeding, or intending to conceive during the course of the study, including the two month follow-up period after drug discontinuation
  7. Known hypersensitivity to the treatment drug or any of its excipients
  8. History of illicit drug use or alcohol abuse within the previous year
  9. History of meningococcal disease
  10. Medical condition that, in the opinion of the investigator, might interfere with the patient's participation in the study, pose an added risk for the patient, or confound the assessment of the patient (e.g. severe cardiovascular or pulmonary disease)
  11. Previously been enrolled in this trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00670774

Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mark Stegall
Alexion Pharmaceuticals
Layout table for investigator information
Principal Investigator: Mark D. Stegall, M.D. Mayo Clinic
  Study Documents (Full-Text)

Documents provided by Mark Stegall, Mayo Clinic:
Additional Information:
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Mark Stegall, MD, Mayo Clinic Identifier: NCT00670774    
Other Study ID Numbers: 07-007208
First Posted: May 2, 2008    Key Record Dates
Results First Posted: June 26, 2018
Last Update Posted: June 26, 2018
Last Verified: May 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Mark Stegall, Mayo Clinic: